Indian pharma stocks drop 1% after Trump signs order to boost US drug manufacturing

Aurobindo Pharma

06/05/2025 09:10

Updates

** Indian pharma stocks .NIPHARM down 1%

** Sixteen stocks in 20-member Nifty Pharma index trade in the red

** U.S. President Donald Trump signed executive order overnight aiming to reduce time taken to approve pharmaceutical plants in the country

** Move meant to boost local drug manufacturing in U.S.

** The policy initiatives, if implemented fully, may lead to increased compliance and operational cost for foreign manufacturers, including those in India, Nuvama analysts say

** Cipla CIPL.NS, Aurobindo Pharma ARBN.NS and Ajanta Pharma AJPH.NS among top losers on index, falling 2%-3%

** Heavyweights Sun Pharma SUN.NS, Dr. Reddys REDY.NS down ~1%

** Most stocks on pharma index rated "hold" or "buy" - data compiled by LSEG

** Pharma index has shed 8% so far this year vs benchmark Nifty 50's .NSEI 3% climb

 (Reporting by Nandan Mandayam and Kashish Tandon in Bengaluru)

 ((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))